The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 12, 2019

Filed:

Jul. 18, 2017
Applicant:

Alderbio Holdings Llc, Las Vegas, NV (US);

Inventor:

Jeffrey T. L. Smith, Bellevue, WA (US);

Assignee:

ALDERBIO HOLDINGS LLC, Las Vegas, NV (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/20 (2006.01); A61K 39/395 (2006.01); C07K 16/24 (2006.01); A61K 31/454 (2006.01); A61K 45/06 (2006.01); C07K 16/46 (2006.01); A61K 49/00 (2006.01); A61K 51/10 (2006.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/3955 (2013.01); A61K 31/454 (2013.01); A61K 38/208 (2013.01); A61K 38/2013 (2013.01); A61K 45/06 (2013.01); A61K 49/0004 (2013.01); A61K 49/0058 (2013.01); A61K 51/1033 (2013.01); C07K 16/248 (2013.01); C07K 16/462 (2013.01); G01N 33/6863 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/41 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/90 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); Y02A 50/412 (2018.01); Y02A 50/58 (2018.01);
Abstract

The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved.


Find Patent Forward Citations

Loading…